The Quantellect read.As of Nov 19, 2026, 4 active firms cover Recursion Pharmaceuticals Inc: 2 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $5.50 to $10.00, a moderate spread. The average target of $7.38 sits 161% above the current $2.83. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral250%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.38
+161.1% upside
Average target across 4 active firms as of Nov 19, 2026 vs $2.83 current
Highest Target$10.00
Average Target$7.38
Lowest Target$5.50
Detailed analyst forecasts for RXRX
Showing 1–5 of 5 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 2 of 4 active firms rate RXRX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RXRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.21 – $-0.17 · 4 analysts · -13% YoY
Next period, 4 analysts expect Recursion Pharmaceuticals Inc to earn $-0.19 a share (range $-0.21 – $-0.17), versus $-0.22 a year earlier. Full-year consensus is $-0.88, growing to $-0.81 the year after.
REVENUE · NEXT QUARTER
$5.9M
Range $2.5M – $9.0M · 4 analysts · -9% YoY
Revenue is expected to reach $5.9M (range $2.5M – $9.0M), -8.8% year-over-year. Full-year consensus is $40.4M, rising to $44.2M next year.
Top analysts covering Recursion Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RXRX.
#1
Gil Blum
Needham · Rank #409
Buy
$8.00+183.2% to target
Overall win rate
27%
+ Follow
#2
Scott Schoenhaus
Keybanc · Rank #540
Buy
$10.00+254.0% to target
Overall win rate
30%
+ Follow
#3
VP
Vikram Purohit
Morgan Stanley
Neutral
$5.50+94.7% to target
Coverage
—
+ Follow
#4
PG
Priyanka Grover
JP Morgan
Buy
$10.00+254.0% to target
Coverage
—
+ Follow
#5
Mani Foroohar
Leerink Partners
Neutral
No targeton RXRX
Coverage
—
+ Follow
RXRX stock forecast FAQ
What is RXRX's average 12-month price target?+
The 4 active firms with a live target average $7.38 for Recursion Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $5.50 low, as of Nov 19, 2026.
Is RXRX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RXRX?+
The Street-high target is $10.00 (JP Morgan), and the Street-low is $5.50 (Morgan Stanley). The average of all 4 active-firm targets is $7.38.
How many active Wall Street firms cover RXRX?+
4 active firms have a recognized rating on Recursion Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RXRX?+
Among analysts who currently cover RXRX, Gil Blum of Needham has the strongest overall Quantellect track record (Rank #409). Their current call is Buy with a $8.00 target.
What is Recursion Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.21 – $-0.17) across 4 analysts. Full-year EPS is projected at $-0.88, rising to $-0.81 the following year.
How much revenue is Recursion Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $5.9M (range $2.5M – $9.0M). Full-year revenue is projected at $40.4M, growing to $44.2M next year.
Have analysts been upgrading or downgrading RXRX lately?+
As of Nov 19, 2026, 2 of 4 active firms rate RXRX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RXRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.